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Abstract Shiga toxin-producing Escherichia coli (STEC) is
associated with hemolytic uremic syndrome (HUS). Although
most clinical isolates of STEC produce hemolysin (called en-
terohemolysin), the precise role of enterohemolysin in the patho-
genesis of STEC infections is unknown. Here we demonstrated
that E. coli carrying the cloned enterohemolysin operon (hlyC,
A, B, D genes) from an STEC human strain induced the pro-
duction of interleukin-1L (IL-1L) through its mRNA expression
but not tumor necrosis factor-K from human monocytes. No
IL-1L release was observed with an enterohemolysin (HlyA)-
negative, isogenic E. coli strain carrying a mutation in the
hlyA gene. The data suggest that enterohemolysin, a pore-form-
ing toxin, induces the production of IL-1L, which is one of
serum risk markers for HUS. ) 2002 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Shiga toxin (Stx)-producing Escherichia coli (STEC; alter-
natively called enterohemorrhagic E. coli, EHEC) belonging
to serotype O157:H7 was identi¢ed as an emerging bacterial
pathogen of food-borne infections in the United States in
1982 [1]. In Japan, during 1996, explosive outbreaks occurred
with more than 17 877 people infected including 12 fatalities
[2]. STEC includes not only serotype O157:H7 (the most prev-
alent serotype), but other serotypes (e.g.) O26, O111, O128,
and O145 have also been implicated in human infections [3,4].
Infection is initially associated with abdominal symptoms
such as abdominal pain, water diarrhea, and hemorrhagic co-
litis and also with serious systemic disorders, such as hemo-
lytic uremic syndrome (HUS), especially in young children
[3^5]. STEC, in many cases, also encodes hemolysin (called
enterohemolysin [6], or EHEC-hemolysin [7]) in addition to
Stx [6]. In the case of the outbreak strains in Japan in 1996,
more than 98% of STEC were positive for enterohemolysin
[8].
Enterohemolysin and K-hemolysin (which is produced from
approximately 50% of E. coli isolates from extraintestinal in-
fections [9], or from porcine STEC strains [6]) are members of
the RTX family, associated with the ATP-dependent HlyB/
HlyD/TolC secretion system through which hemolysin
(HlyA) is secreted across the bacterial membranes. Both the
enterohemolysin and K-hemolysin operons consist of the hlyC,
hlyA, hlyB, and hlyD genes [10^12].
Enterohemolysin and K-hemolysin are, however, genetically
and immunologically distinct hemolysins. Enterohemolysin is
a cell-associated hemolysin, in contrast to K-hemolysin which
is released from bacterial cells [7]. In the case of enterohemo-
lysin, hemolysis is observed on blood agar containing washed
but not unwashed sheep erythrocytes, in sharp contrast to
K-hemolysin, which is detected even on blood agar containing
unwashed sheep erythrocytes [6].
In HUS, it has been shown that serum levels of proin£am-
matory cytokines such as interleukin-1L (IL-1L) and tumor
necrosis factor-K (TNF-K) are elevated [13^15]. Both IL-1L
and TNF-K regulate the expression of the Stx receptor (a
glycolipid globotriosylceramide, Gb3) on the endothelial cell
membrane [16,17]. Bacterial lipopolysaccharide (LPS) and Stx
stimulate the production of IL-1L and TNF-K from human
monocytes [17,18]. However, whether enterohemolysin in-
duces the production of proin£ammatory cytokines has not
yet been investigated.
In the present study, we investigated if E. coli carrying the
cloned enterohemolysin genes elicited proin£ammatory cyto-
kines from human monocytes. For this, we constructed an
enterohemolysin-negative (hlyA) derivative from the cloned
enterohemolysin genes, and evidence was provided that en-
terohemolysin produces IL-1L, but not TNF-K, from human
monocytes.
2. Materials and methods
2.1. Bacterial strains and plasmid
STEC human strain F60 (serotype O128:H12) was isolated on oc-
casions of outbreaks of STEC infections in Japan in 1996. It produces
both Stx1 and Stx2, and manifests enterohemolysin activities in a
great quantity, compared with other STEC human strains isolated
from Japan [8]. E. coli HB101 is a hybrid between E. coli K-12 and
E. coli B, lacks restriction ability, and was used as a host of recombi-
nant plasmids.
0014-5793 / 02 / $22.00 K 2002 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 2 ) 0 3 0 2 7 - 2
*Corresponding author. Fax: (81)-25-227 0762.
E-mail address: tatsuoy@med.niigata-u.ac.jp (T. Yamamoto).
Abbreviations: STEC, Shiga toxin-producing Escherichia coli ; Hly,
hemolysin; IL-1L, interleukin-1L ; TNF-K, tumor necrosis factor-K ;
HUS, hemolytic uremic syndrome; RT-PCR, reverse transcription-
polymerase chain reaction; Stx, Shiga toxin
FEBS 26317 19-7-02 Cyaan Magenta Geel Zwart
FEBS 26317 FEBS Letters 524 (2002) 219^224
The recombinant plasmid pACH1 (24.5 kbp in size) carried the
entire enterohemolysin operon (hlyC, hlyA, hlyB, hlyD genes) which
originated in the enterohemolysin-positive plasmid pO128-60 (120 kbp
in size) of STEC strain F60 [8]. The GenBank accession number for
the gene sequence of this enterohemolysin operon is AB032930. The
determined sequence covers the 7 869-nucleotide sequence of the en-
terohemolysin operon region, including the entire enterohemolysin
genes (hlyC, hlyA, hlyB, hlyD) (7 127 bp; Fig. 1), the 477-nucleo-
tide-upstream region from the hlyC gene, and the 265-nucleotide-
downstream region to the hlyD gene.
2.2. Construction of a mutant hlyA gene
For mutagenesis of the hlyA gene, the pACH1 plasmid DNA carry-
ing the entire enterohemolysin operon was cut with SplI, whose site
was located 81 bp downstream to the initiation codon ATG within
hlyA. The generated single stranded ends were polymerized and the
two resultant double-stranded ends of the linear pACH1 DNA were
ligated using a DNA blunting kit (Takara Shuzo Co., Shiga, Japan).
The plasmid (pACHT1) thus obtained was subjected to sequence
analysis for the whole mutant enterohemolysin operon region, as de-
scribed above. pACHT1 was used in experiments on hemolysis and
cytokine production.
2.3. Media and bacterial growth
For bacterial growth, tryptic soy agar (Difco Laboratories, Detroit,
MI, USA) was used as solid media. We used antibiotics (20 Wg of
chloramphenicol per ml) to maintain the recombinant plasmids during
cultivation.
Luria^Bertani (LB) broth (Difco) was used as liquid media which
was inoculated and incubated at 37‡C for 12^18 h with agitation. In
some experiments, RPMI 1640 medium (ICN Biomedicals, Aurora,
OH, USA) supplemented with 10% fetal bovine serum (Gibco BRL,
Grand Island, NY, USA) was also employed. When bacteria were
grown in the liquid media, antibiotics were not added. In the case
of E. coli HB101 carrying pACH1 or pACHT1, after incubation, a
portion of the liquid culture was streaked on tryptic soy agar and the
colonies developed were examined for the presence of the recombinant
plasmid (chloramphenicol-resistant) with the replica plating method.
All of the colonies examined were resistant to chloramphenicol
(20 Wg/ml).
2.4. Hemolysis assay
For hemolysis assay on agar plates, bacteria were streaked on tryp-
tic soy agar supplemented with 5% fresh, washed, de¢brinated sheep
erythrocytes and 10 mM CaCl2 [6]. The inoculated plates were then
incubated for 3 to 24 h at 37‡C. Hemolysis occurring around the
streaked bacterial colonies was examined with the naked eye.
Hemolysis assay using liquid cultures was performed essentially by
the method previously described [19]. Bacterial cells were added at
1U107 CFU/ml to tryptic soy broth (Difco) supplemented with 5%
sheep blood cells and 10 mM CaCl2, and incubated at 37‡C for 6 h.
The mixture was then centrifuged, and the quantity of hemoglobin
released from lysed blood cells was measured in the supernatant by
spectrophotometry (wavelength, 540 nm). The same quantity of blood
cells was added to distilled water, and the quantity of hemoglobin
released was regarded as the total hemolysis (A540 of total), and
the percent lysis with each sample was calculated by the equation,
percent lysis = 100U(A540 of sample3A540 of background)/(A540
of total3A540 of background).
2.5. Cytokine assay
For cytokine induction experiments, human mononuclear cells were
prepared from peripheral blood using Ficol-Hypaque (Gibco BRL).
Adherent monocytes were obtained after incubation in 24-well culture
plates (A/S Nunc, Roskilde, Denmark) for 60 min at 37‡C in a CO2
incubator with subsequent washing under high pressure [20]. For
treatment of monocytes with stimuli, bacteria with or without the
hemolytic phenotype were ¢rst grown in LB broth, suspended in
RPMI 1640 medium supplemented with 10% fetal bovine serum and
grown to the log-phase, after which culture supernatants were pre-
pared. The culture supernatants were incubated with the monocytes
(approximately 105 cells per ml) for 2^6 h at 37‡C in a CO2 incubator.
IL-1L and TNF-K in the supernatants were assayed with IL-1L and
TNF-K kits (Genzyme, Cambridge, MA, USA) in accordance with the
manufacturer’s instructions.
2.6. Cytokine mRNA assay
To detect mRNA, after incubation, total cellular RNA of the
monocytes was extracted using acid guanidinium thiocyanate/phe-
nol/chloroform. The amount of RNA was assessed with a RiboGreen
RNA quantitation kit (Molecular Probes, Inc., The Netherlands).
A reverse transcription-polymerase chain reaction (RT-PCR) was
performed as described previously [21]. Primers for IL-1L (5P-AAA-
CAGATGAAGTGCTCCTTCCAGG and 5P-TGGAGAACACCA-
CTTGTTGCTCCA, generating a 391-bp product), TNF-K (5P-
GGACGTGGAGCTGGCCGAGGAG and 5P-CACCAGCTGGT-
TATCTCTCAGCTC, generating a 352-bp product), and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) (5P-GGGAGCCAAA-
AGGGTCATCATCTC and 5P-CCATGCCAGTGAGCTTCCCG-
TTC, generating a 353-bp product) were kindly provided by Dr.
Yasuhiro Natori (International Medical Center of Japan, Tokyo, Ja-
pan) [22,23]. Negative controls were performed by omitting RNA
from cDNA synthesis and speci¢c PCR ampli¢cation. Cycling con-
ditions were denaturation for 45 s at 94‡C, annealing for 45 s at 55‡C,
and polymerization for 45 s at 72‡C (35 cycles). Ampli¢ed PCR prod-
ucts were analyzed by gel electrophoresis with 2% agarose and stained
with ethidium bromide. PX174 RF DNA/HaeIII fragments (Life
Technologies, Gaithersburg, MD, USA) were used as molecular size
standards.
2.7. Data analysis
Data were presented as mean SS.D. of triplicate experiments, and
evaluated by Mann^Whitney’s U-test.
3. Results
3.1. Construction of pACHT1 carrying the mutant hlyA gene
The enterohemolysinþ recombinant plasmid pACH1 car-
ried the unique SplI site within the hlyA gene (Fig. 1).
pACH1 DNA was cut with SplI and ¢lled in with DNA poly-
merase, and the plasmid pACHT1 carrying the mutant hlyA
gene was constructed. The mutant hlyA gene carried the
CGTACGTACG sequence (4-base GTAC insertion) instead
of the CGTACG sequence (SplI site), resulting in a frame
shift from the 31st codon and a new stop codon at the posi-
tion of the 42nd codon (Fig. 1). The deduced amino acid
sequence of the mutant hlyA gene is only 41 amino acids
long, in contrast to that of the intact hlyA gene (998 amino
acids long). There were no other mutations within the entero-
hemolysin operon.
3.2. Hemolytic phenotype
Bacterial cells of a wild-type STEC strain F60 (from which
the enterohemolysin operon was cloned), E. coli HB101, E. coli
HB101 carrying pACH1, or E. coli HB101 carrying pACHT1
were streaked on blood agar plates, and the plates were incu-
bated for 3^24 h at 37‡C. When blood agar plates with
washed sheep erythrocytes were employed, hemolysis by
STEC strain 60 was observed 12^24 h after incubation at
37‡C, as shown in Fig. 2A(1). Hemolysis by E. coli HB101
carrying pACH1 was much greater than that by STEC strain
F60 (Fig. 2A(3)), and was visible as early as 3 h after incu-
bation at 37‡C. No detectable hemolysis occurred on blood
agar plates not supplemented with CaCl2 or made of un-
washed sheep erythrocytes, as shown in Fig. 2B(1,3).
In the case of E. coli HB101 or E. coli HB101 carrying
pACHT1, hemolysis was not observed even with washed
sheep erythrocytes or even after prolonged incubation for
24 h at 37‡C, as shown in Fig. 2A(2,4).
The hemolytic activities were also evaluated in liquid cul-
tures (Fig. 2C). The hemolytic activity of E. coli HB101 car-
rying pACH1 was 2.1-fold greater, as compared with the he-
FEBS 26317 19-7-02 Cyaan Magenta Geel Zwart
I. Taneike et al./FEBS Letters 524 (2002) 219^224220
molytic activity of STEC strain F60 (Fig. 2C, (3) vs.(1)). The
hemolytic activity of E. coli HB101 carrying pACHT1 was not
signi¢cantly observed.
3.3. Enterohemolysin-mediated production of cytokines
Bacterial cells of STEC strain F60, E. coli HB101, E. coli
HB101 carrying pACH1, or E. coli HB101 carrying pACHT1
were grown in a liquid medium. Subsequently, the culture
¢ltrates were incubated with monocytes from human periph-
eral blood for 2 h at 37‡C, and cytokines in the supernatants
were assayed. The culture ¢ltrates of E. coli HB101 carrying
pACH1 induced the expression of IL-1L, but not TNF-K from
Fig. 1. A restriction endonuclease cleavage map of the recombinant plasmid pACH1 carrying the enterohemolysin operon and of the plasmid
pACHT1 carrying the mutant hlyA gene. pACH1 consists of pACYC184 (a cloning vector, 4.2 kbp) and a BamHI fragment (20.3 kbp) origi-
nating from the Hlyþ plasmid (pO128-60) of a human STEC strain. It exhibits an enterohemolysin phenotype and chloramphenicol resistance
of pACYC184. C, A, B, and D in boxes represent the hlyC, hlyA, hlyB, and hlyD genes, respectively; the numbers above boxes represent
DNA sizes (in bp). In the lower part of this ¢gure, the nucleotide sequences surrounding the SplI site in pACH1 and the SplI-blunt-end-ligated
site in the mutant plasmid (pACHT1) are shown. The SplI site in pACH1 represents a unique site, located over the 28th codon position within
the hlyA gene. pACHT1 was constructed by restriction and a subsequent ¢ll-in reaction. The electropherogram on the right shows the sequenc-
ing data around the SplI site in pACH1 and the corresponding site in pACHT1.
Fig. 2. Hemolytic phenotype of a wild-type STEC strain F60 and E. coli HB101 carrying pACH1 (with the intact hlyA gene) or pACHT1
(with the mutated hlyA gene). Hemolysis was assayed on agar plates in A and B, and in liquid cultures in C. Bacterial cells used were: 1, STEC
strain F60; 2, E. coli HB101; 3, E. coli HB101 carrying pACH1; 4, E. coli HB101 carrying pACHT1. In A, streaked blood agar plates contain-
ing washed sheep erythrocytes were incubated for 24 h at 37‡C. A clear zone of hemolysis (around the streaked bacterial colonies) can be seen
in 1, and a larger zone of hemolysis in 3. No detectable hemolysis occurred in 2 or 4. Hemolysis in 3 occurred as early as 3 h after incubation
at 37‡C. In B, streaked blood agar plates containing unwashed sheep erythrocytes were incubated for 24 h at 37‡C. No detectable hemolysis
occurred. In C, sheep erythrocytes were incubated with bacteria in a liquid medium for 6 h at 37‡C, and the quantity of hemoglobin released
from lysed blood cells was measured by spectrophotometry (wavelength, 540 nm) and percent lysis was estimated. The results are presented as
meanSS.D. of triplicate experiments. *P6 0.05, **P6 0.01 as compared with the data of E. coli HB101.
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human monocytes (Fig. 3(3)). The IL-1L response was dimin-
ished when E. coli HB101 carrying pACHT1 was used (Fig.
3(4). This was the case even after 6 h of incubation.
In contrast to E. coli HB101 carrying pACH1, a wild-type
STEC strain F60 induced the expression of both IL-1L and
TNF-K from human monocytes (Fig. 3(1)). The IL-1L expres-
sion level observed was lower, compared with that for E. coli
HB101 carrying pACH1 (P6 0.05).
3.4. Enterohemolysin-mediated cytokine mRNA expression
The culture ¢ltrates of E. coli HB101 carrying pACH1 in-
duced the expression of IL-1L mRNA (Fig. 4, lane 2), while
the culture ¢ltrates of E. coli HB101 or E. coli HB101 carrying
pACHT1 did not (Fig. 4, lanes 1 and 3). The house-keeping
gene GAPDH (cDNA) was simultaneously ampli¢ed in par-
allel tubes (Fig. 4, lanes 4^6), indicating equivalent loading of
the samples. The speci¢city of the RT-PCR products was
con¢rmed by restriction enzyme digestion; HindIII digestion
generating 82- and 309-bp fragments for IL-1L (the GenBank
accession number for the IL-1L sequence, X02532), and MspI
digestion generating 119- and 234-bp fragments for GAPDH
(the GenBank accession number for the GAPDH sequence,
M17851).
4. Discussion
The precise role of enterohemolysin in the pathogenesis of
STEC infections is still unknown. However, the following in-
formation has been accumulated and indicates an association
of enterohemolysin with clinical diseases in humans: (i) most
clinical isolates of STEC produce enterohemolysin [6^8],
(ii) enterohemolysin lyses erythrocytes resulting in release of
heme and hemoglobin, which serve as sources of iron and
stimulate the growth of STEC [24], (iii) in the case of STEC
belonging to serotype O111:H-, enterohemolysin was ob-
served in 88% of strains from patients with HUS, but only
in 22.2% of strains from patients with diarrhea, indicating
that the presence of enterohemolysin increases the ability of
STEC O111 to cause extraintestinal complications in humans
[25], (iv) antibodies to enterohemolysin have been detected in
the sera of patients with HUS [7], (v) E. coli O157:H- strains
that did not produce Stx, but did produce enterohemolysin,
have been isolated from HUS patients [26].
STEC belonging to serotype O157:H7, however, does not
e¡ectively secrete enterohemolysin in the culture supernatant.
And, when the hlyB and hlyD genes of the K-hemolysin oper-
on are supplied, STEC O157:H7 becomes able to induce he-
molytic activity [7].
The enterohemolysin used in this study (which originated
from STEC belonging to serotype O128:H12) is better se-
creted from E. coli cells compared with STEC O157:H7. In
the case of O128:H12, the HlyB has only one methionine
residue at the amino terminus (the same as K-hemolysin), in
sharp contrast to O157-HlyB, which has two repeated methio-
nine residues at the amino terminus (as a consequence, the
O157-HlyB is longer than O128-HlyB by one amino acid) [8].
It is thought that the transmembrane domain of HlyB con-
stitutes a pocket which binds with HlyA (the signal sequence
at the carboxy terminus of HlyA), while the ATP-binding
domain (located at the cytoplasm side) of HlyB generates
energy for the transport [27]. There is the possibility that
the amino terminal sequence of the O157-HlyB possessing
two repeated methionine residues interferes with the transpor-
tation of HlyA.
Although the present O128-HlyA was also slightly diver-
gent from the reported O157-HlyA with a homology of
98.5% at the amino acid level [8], both HlyAs shared the
same enterohemolysin phenotype on blood agar plates, the
same predicted sites for acylation (Lys-550 and Lys-675),
and almost identical RTX repeat sequences (glycine- and as-
partate-rich Ca2þ-binding repeats) [7,8,28]. Both the O128-
Fig. 3. IL-1L production from human monocytes. Bacteria used
were: 1, Hlyþ STEC strain F60; 2, E. coli HB101; 3, Hlyþ E. coli
HB101 carrying pACH1; 4, Hly3 E. coli HB101 carrying pACHT1.
The bacterial culture supernatants were incubated with the mono-
cytes (approximately 105 cells per ml) for 2 h at 37‡C in a CO2 in-
cubator, and then the IL-1L and TNF-K in the supernatants were
assayed. The data are shown with a closed bar and an open bar, re-
spectively, in the ¢gure. The results are presented as meanSS.D. of
triplicate experiments. Marked IL-1L production was observed with
E. coli HB101 (pACH1), but not with E. coli HB101 or E. coli
HB101 (pACHT1), even after 6 h of incubation. TNF-K production
was not stimulated in any case (except for STEC strain F60).
*P6 0.01, as compared with the level of IL-1L stimulation by E. coli
HB101 or E. coli HB101 (pACHT1); P6 0.05, as compared with
the level of IL-1L stimulation by STEC strain F60.
Fig. 4. IL-1L mRNA expression in human monocytes. Human
monocytes stimulated for 2 h as in Fig. 3 were procured and total
cellular RNA was extracted. The mRNA was reverse-transcribed
and ampli¢ed with primers for IL-1L (lanes 1 to 3) or for GAPDH
(lanes 4 to 6). Stimulation of monocytes was E. coli HB101 in lanes
1 and 4, Hlyþ E. coli HB101 carrying pACH1 in lanes 2 and 5, and
Hly3 E. coli HB101 carrying pACHT1 in lanes 3 and 6. A represen-
tative experiment of three identical experiments is shown. Similar re-
sults were obtained even after 6 h of stimulation.
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HlyA and O157-HlyA are very divergent from K-HlyA in
terms of amino acid length (25 amino acids shorter) and a
homology at the amino acid level (61.9% and 6l.2^61.6%,
respectively).
In this study, we constructed a mutant hlyA gene in which
only the ¢rst 29-amino acid sequence at the N terminus (cor-
responding to 2.9% of the predicted HlyA amino acid se-
quence) was conserved. The enterohemolysin operon carrying
this mutant hlyA gene displayed an enterohemolysin-negative
phenotype. By using an E. coli strain carrying the intact en-
terohemolysin operon and an isogenic E. coli strain with the
mutant hlyA gene, we clearly demonstrated that enterohemo-
lysin of a human STEC strain caused the release of IL-1L (but
not TNF-K) from human monocytes.
When the enterohemolysin operon of STEC strain F60 was
cloned into the pACYC184 (vector with medium copy num-
ber), E. coli HB101 carrying the recombinant plasmid
(pACH1) produced more hemolysin on blood agar plates as
well as in liquid cultures. In the latter case, a 2.1-fold greater
hemolytic activity was observed as compared with STEC
strain F60. In agreement with this, E. coli HB101 carrying
pACH1 exerted a greater stimulatory e¡ect on human mono-
cytes, and produced more IL-1L. However, since STEC strain
F60 produces both Stx and enterohemolysin, further experi-
ments should be performed with STEC strain F60 and its
hemolysin-negative (or Stx-negative) mutant to evaluate the
stimulatory e¡ects.
In this study, only IL-1L and TNF-K stimulation was ex-
amined using human monocytes. Since enterohemolysin is a
pore-forming toxin with multiple stress functions on eukary-
otic cells, it remains unclear whether the increase in IL-lL is a
speci¢c process or whether it is the cause of the more global
cytotoxic e¡ect. Measurement of other cytokines to control
the experiments need to be performed.
Around 10% of children infected with STEC develop HUS
[29]. HUS is recognized as acute renal failure, with microan-
giopathic hemolytic anemia and thrombocytopenia [30], and a
variety of circulating in£ammatory mediators increase during
thrombotic microangiopathies, including IL-1L, TNF-K, IL-6
and IL-8 [13^15,31].
Experimental data suggest that the host’s in£ammatory re-
sponses to Stx are involved in the development of HUS. Stx
binds to the functional receptor, globotriaosylceramide (Gb3),
on human endothelial cells [32,33], monocytes [17], and renal
tissue [34]. Stx induces the production of IL-1L, TNF-K, IL-6
and IL-8 from human monocytes [17]. In addition, synthesis
of Gb3 is increased by IL-1L and TNF-K, and a combination
of Stx and a cytokine exhibits a marked synergistic cytotox-
icity on human vascular endothelial cells [33,35,36].
Several hemolysins or cytotoxins have been shown to play a
role in pathogenicities via the production of cytokines. Pneu-
molysin, the membrane-damaging toxin of Streptococcus
pneumoniae, stimulates the production of IL-1L and TNF-K
by human monocytes in vitro [37]. In addition, pneumolysin
(and its truncated, non-cytolytic products with C-terminal de-
letions) has been shown to be capable of inducing IFN-Q
production in spleen cells by a mechanism di¡erent from
pore formation [38]. The K-toxin of Staphylococcus aureus, a
transmembrane pore-forming toxin, activates NF-UB and in-
duces IL-8 production [39]. Group B streptococcal (GBS)
L-hemolysin production has been shown to be associated
with systemic and intra-articular IL-6 and IL-1L levels [40].
Furthermore, GBS L-hemolysin induces nitric oxide produc-
tion via the NF-UB activation [41].
In the case of E. coli K-hemolysin, the acylated, hemolyti-
cally active form elicits IL-1L release by monocytes, and the
acylated K-hemolysin (but not IL-1L) appears to be a critical
mediator of the lethality in mice, to which K-hemolysin-pro-
ducing E. coli was given intraperitoneally [42]. However, since
STEC colonizes the intestinal mucosa and usually does not
invade, STEC can not act as an extraintestinal, bacterial dis-
patcher of enterohemolysin.
K-Hemolysin production in STEC has been reported. A
well-known example is the case of porcine STEC which colo-
nizes the porcine intestinal mucosa, and produces Stx2e (an
Stx2 variant) and K-hemolysin (instead of enterohemolysin).
The K-hemolysin-producing porcine STEC causes edema dis-
ease [43].
In humans, enterohemolysin may contribute to the develop-
ment of HUS via the production of IL-1L from human mono-
cytes. In addition, enterohemolysin may mediate translocation
of other stimulating proteins such as Stx, as Gram-positive
bacterial cytolysin (pore-forming toxin) mediates transloca-
tion of bacterial e¡ector proteins into host cells [44].
Studies are required with enterohemolysin to clarify its role
in STEC pathogenesis.
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